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Abstract:  
Anticholinergic drugs are prescribed for a range of conditions including gastrointestinal disorders, 
overactive bladder, allergies, and depression. While in some circumstances anticholinergic effects are 
therapeutic, they also pose many undesired or adverse effects. The overall impact from concomitant 
use of multiple medications with anticholinergic properties is termed “anticholinergic burden” (ACB). 
Greater ACB is associated with increased risks of impaired physical and cognitive function, falls, 
cardiovascular events and mortality. This has led to the development of interventions aimed at 
reducing ACB through the deprescribing of anticholinergic drugs. However, little is known about the 
implementation issues that may influence successful embedding and integration of such interventions 
into routine clinical practice. In this paper we present the protocol for our systematic review that aims 
to identify the qualitative evidence for the barriers and facilitators to reducing ACB from the 
perspectives of patients, carers and healthcare professionals. A comprehensive search strategy will be 
conducted across OVID Medline, EMBASE, PsycInfo and CINAHL. The review will be conducted in 
accordance with ENTREQ (Enhancing Transparency in Reporting the Synthesis of Qualitative 
Research) and has been registered with PROSPERO (Registration CRD42018109084). Normalization 
Process Theory (NPT) will be used to explore, understand and explain qualitative data in relation to 
factors that act as barriers or facilitators to ACB reduction.  





Anticholinergic drugs block the actions of acetylcholine and prevent parasympathetic nerve 
activity [1]. In some circumstances these anticholinergic actions have intended therapeutic effects, for 
example, the use of amitriptyline in the treatment of chronic pain, but in others, they are a side effect 
of a drug used primarily for other pharmacological actions, such as Atenolol [2]. Anticholinergic drugs 
are prescribed for a wide range of conditions including gastrointestinal disorders, overactive bladder, 
allergies, depression, psychosis and cardiovascular disease [1-3] resulting in a high overall prevalence 
of these medications. Anticholinergic drugs have many adverse effects that include dry mouth, 
constipation, increased heart rate, confusion, and increased risk of falls [1-2].  Older people are more 
susceptible to these side effects [2]. The prescribing of multiple medicines for older adults in response 
to managing multiple morbidities in later life places them at greater risk of being exposed to 
anticholinergic drugs [2].  
 
Population surveys suggest that up to 50% of community dwelling older adults may be taking one 
or more medications with anticholinergic effects [4-6]. The potential impact of anticholinergics on an 
individual is termed as “anticholinergic burden” (ACB) [2], and concomitant use of multiple medications 
with anticholinergic properties has a cumulative effect [2,7]. Several scales to assess ACB have been 
developed, such as the Anticholinergic Drug Scale [8], Anticholinergic Cognitive Burden Scale [9] and 
the Anticholinergic Risk scale [10]. Several recent systematic reviews have reported that greater ACB is 
associated with increased risk of impaired physical and cognitive function, falls, cardiovascular events 
and mortality [11-15].  These findings have led to the development of interventions aimed at reducing 
ACB through either stopping anticholinergic medications (deprescribing) or changing them to 
medicines that do not have anticholinergic properties. Therefore, understanding factors that will 
influence efforts to reduce this burden would be an important step forward. 
 
Our recent systematic review identified eight studies that aimed to reduce ACB amongst older 
adults (PROSPERO registration CRD42018089764). Interventions varied widely regarding their design 
and setting (e.g. community, nursing homes, acute care), person delivering the interventions (e.g. 
pharmacist, pharmacologist, physician), and how recommendations were identified and made (e.g. 
face to face, over the telephone or virtually). Seven of the eight studies reported positive improvements 
regarding ACB. Despite interest in conducting ACB reduction interventions, little is known about 
implementation issues. Specifically, what factors increase or decrease successful embedding and 
integration of such interventions.  The current evidence base is limited to specific population groups, 
such as those on particular types of anticholinergic medications such as antipsychotics [2]. In relation 
to ‘deprescribing’ in general, several systematic reviews have revealed common barriers and facilitators 
[16-19]. There is overlap between factors reported by patients and prescribers including fears of 
negative consequences arising from stopping medications, and a lack of ongoing support [16-19]. 
Conversely, patient motivation, support for the prescriber and patient, and beliefs that deprescribing 
is the right thing to do, all support the deprescribing process [16-19]. However, it is unknown if the 
barriers and facilitators towards reducing use of anticholinergic drugs are different from those for 
general deprescribing of inappropriate medications, or if anticholinergic drugs and medical conditions 
associated with their use, may present unique challenges. Investigating barriers and facilitators to 
anticholinergic deprescribing is essential to inform the development and design of ACB reduction 
interventions [20].   To the best of our knowledge, this is the first study to systematically review primary 
qualitative studies exploring the barriers and facilitators to ACB reduction. Our aim is to identify and 
describe the evidence regarding such factors from the perspectives of patients, their carers (or proxy 




Our specific research questions are:  
1. What are the barriers and facilitators to reducing patient ACB from the perspective of 
healthcare professionals? 
2. What are the barriers and facilitators to reducing patient ACB from the perspective of patients 
and carers? 
Methods  
A systematic literature search and evidence synthesis  of  published papers that contain qualitative 
data is being conducted based on the general principles of the Cochrane Handbook for Systematic 
Reviews of Interventions [21], and ENTREQ (Enhancing Transparency in Reporting the Synthesis of 
Qualitative Research) [22]. This review has been registered with PROSPERO (Registration 
CRD42018109084). Any methodological changes made will be recorded in revisions of the study protocol 




This review will use a modified PICO (population, intervention, control and outcome) framework to 
describe our inclusion and exclusion criteria [23]. Eligibility criteria are presented in Table 1. Language 





Four electronic databases will be searched: Ovid MEDLINE, EMBASE, CINAHL and PsycIINFO. 
The search strategy will be developed for Ovid MEDLINE and adapted as needed for other databases 
where appropriate. Scoping searches to identify appropriate subject headings, key words and text words, 
will be completed for each database. This will involve using the MeSH mapping tool to identify relevant 
and related search terms, and reviewing the indexing of, references within and citations for, known 
relevant and closely related manuscripts. Bibliographies of included publications will also be searched 
manually for additional potentially eligible papers. We will also review papers citing the included articles 




The search strategy will adopt a concepts-based approach, the concepts of interest being ACB, 
interventions to reduce ACB, and qualitative methods. A search strategy is presented in supplementary 
file S1.  
 
Data collection and analysis: 
 
Identified studies will be transferred into RefWorks (ProQuest LLC) [24] for bibliographic 
management and transferred to Covidence (Veritas Health Innovation Ltd) [25] for title and abstract 
screening. Two independent reviewers will screen article titles, abstracts and full papers using the 
inclusion and exclusion criteria shown in Table 1. Full-texts of potentially eligible studies will be obtained 
and study authors will be contacted where full-texts cannot be found. Any discrepancies in eligibility 
between the two reviewers will be resolved by an independent third reviewer.  
A standardised data extraction form will be developed to ensure consistent data collection from all 
studies.  Items from standard reporting checklists will be included in the form as follows: The Cochrane 
Handbook for Systematic Reviews of Interventions [21], and ENTREQ (Enhancing Transparency in 
Reporting the Synthesis of Qualitative Research) [22].  Two reviewers will be involved in data extraction 
and disagreements discussed and resolved within the wider research team.  
 
Studies quality assessment: 
 
Two reviewers will independently assess risk of bias of included studies using the relevant Critical 




Two reviewers will conduct data analysis with a third party for arbitration of disagreements. 
Qualitative data will be exported into NVivo, version 12, QSR International [27] to facilitate data analysis. 
Normalization Process Theory (NPT) will serve as the underpinning conceptual framework to explore, 
understand and explain the qualitative data in relation to factors that act as barriers or facilitators to ACB 
reduction. NPT is a well-developed theory for understanding such factors from the perspective of 
intervention implementation [28-32].  NPT consists of four constructs: coherence, which addresses the 
sense-making work that people participating in an intervention have to undertake; cognitive 
participation, the engagement work that is undertaken to ensure participants ‘buy into’ the intervention; 
collective action, the operational work and tasks that people have to do to enact the intervention; and 
reflexive monitoring, the appraisal work people undertake in relation to the intervention [29].  Data will 
be analysed using a framework underpinned by NPT. A coding sheet detailing and describing the themes 
required to be explored by NPT will be developed and agreed by the team. This will provide a framework 
for sorting and categorising the data, and exploring relationships between themes.  The framework will 
be refined and adapted during data analysis and will be flexible to enable data that falls outside of our 
conceptual model to be captured. 
Discussion 
To date, the search strategies have been conducted and screening of identified articles is underway. 
The findings of this review will be used to inform development and design of a future trial examining 
the efficacy of an ACB reduction intervention. The Medical Research Council [20] recommends that 
interventions be developed from evidence accrued from systematic reviews. They also recommend 
examining this evidence to develop understanding of the theoretical underpinnings of the intervention 
[20].  This review will identify if there are key research gaps.  For example, if the quantity and quality 
of identified evidence are found to be insufficient, future qualitative research may be required to 
answer outstanding implementation questions. Our use of a robust theoretical framework to underpin 
our data analysis will help us to move from a purely descriptive account to one that is more explanatory 
in nature.  The use of such approaches is advocated when developing complex interventions [20]. 
Dissemination plans include one peer-reviewed manuscript and conference presentations and/or 
public engagement events.   
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Table 1 Study Eligibility Criteria 
 Inclusion Criteria Exclusion Criteria 
Population 
(Participants) 
 Persons aged ≥18 years of age  
 Persons using one or more 
anticholinergic medications 
 Carer/ proxy (e.g. a person answering 
on behalf of the patient) for an adult 
using one or more anticholinergic 
medications 
 Healthcare professional (e.g. 
physicians, nurses, pharmacists) 
involved in the care of adults using one 
or more anticholinergic medications 
 Persons aged < 18 years 
 
Setting  Primary care 
 Community  
 Nursing home 
 Outpatient clinics 
 Day hospitals/centres/care facilities 
 Rehabilitation services 
 Acute care/ inpatients 
 Palliative care 
Intervention   Original research findings examining 
attitudes to deprescribing/medication 





Study Type / 
Design 
 Qualitative research ( face-to-face or 
telephone approaches) 
 Full papers published in peer-reviewed 
journals 
 Published in English 
 Quantitative research 
Controls  None  
Outcome  Barriers and facilitators to 
deprescribing or medication switching 
in relation to  anticholinergic 
medications 
 
 
 
